Ultragenyx Pharmaceutical reported $-1.29 in EPS Earnings Per Share for its fiscal quarter ending in December of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q4 Dec/2025 -1.29 -1.17 -1.39 Feb/12 2026
FY2025Q3 Sep/2025 -1.81 -1.23 -1.40 Nov/04 2025
FY2025Q2 Jun/2025 -1.17 -1.29 -1.52 Aug/05 2025
FY2025Q1 Mar/2025 -1.57 -1.53 -2.03 May/06 2025
FY2024Q4 Dec/2024 -1.39 -1.34 -1.52 Feb/13 2025




Eps Change Date
Acadia Pharmaceuticals USD 0.42 0.26 Sep/2025
Agios Pharmaceuticals USD -1.86 0.08 Dec/2025
Alnylam Pharmaceuticals USD 1.25 1.65 Dec/2025
BioCryst Pharmaceuticals USD -0.13 0.06 Dec/2024
BioMarin Pharmaceutical USD 0.46 0.34 Dec/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Immunic USD -0.24 0.03 Sep/2024
Insmed USD -1.54 0.21 Dec/2025
Ionis Pharmaceuticals USD -0.8 1.5 Sep/2025
Karyopharm Therapeutics USD -0.15 0.11 Dec/2024
Kyowa Hakko Kirin JPY 65.79 34.69 Dec/2025
MacroGenics USD 0.27 0.84 Sep/2025
Moderna USD -2.11 1.6 Dec/2025
Neurocrine Biosciences USD 1.88 0.29 Dec/2025
PTC Therapeutics USD -1.67 1.87 Dec/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 11.44 0.39 Dec/2025
Sarepta Therapeutics USD -0.13 2.15 Sep/2025
Ultragenyx Pharmaceutical USD -1.29 0.52 Dec/2025
Vertex Pharmaceuticals USD 5.03 0.23 Dec/2025
Xoma USD -1.59 2.43 Sep/2024